MERCK-KGAA·Life-science tools & bioprocessing (Life Science) + specialty/rare-disease pharma (Healthcare) + electronic/semiconductor materials (Electronics)

Merck KGaA

ConvictionContext

Three-sector diversified operating company: (1) Life Science sells consumables/reagents, bioprocessing (Process Solutions), lab products and services to biopharma & academia; (2) Healthcare develops and markets prescription drugs (oncology, neurology/MS, fertility, rare disease); (3) Electronics supplies specialty materials for semiconductor fabs and displays. Razor/razor-blade recurring consumables in Life Science + Electronics; patent-cliff pharma economics in Healthcare. Growth via secular tailwinds + serial M&A (Millipore, Sigma-Aldrich, Versum, SpringWorks, pending Bio-Techne).

Revenue

EUR21.1B FY2025~$24B USD

Rev growth

+3.1% organic FY2025reported -0.3% (roughly flat) as an FX headwind of ~-3.7% offset organic growth. Q1 2026: +2.9% organic, -2.8% reported

Gross margin

not separately disclosedin retrieved sources; group is consumables/specialty-materials heavy (structurally high gross margin, ~60%+ historically) but not verified here — treat as not disclosed

Op margin

EBITDA-pre margin 28.9% of net sales FY2025EUR6.1B on EUR21.1B); reported EBIT margin lower and not precisely disclosed here

Capex intensity

elevated — historically ~8-10% of sales as Merck expands bioprocessing and semiconductor-materials capacityFY2025 exact figure not confirmed in retrieved sources (not disclosed here

Market cap

~EUR63B~$72B USD) — Frankfurt/Xetra (ETR:MRK, ISIN DE0006599905), ~EUR145.65/share on 28-Jun-2026

The read

Where our coverage leans

Coverage leans bullish

Members only

Full financial intelligence for Merck KGaA

Earnings, margins & COGS, the income-statement breakdown, SWOT, moats & dependencies, the supplier–customer ecosystem graph, top signals & trends, and the valuation range.

Income statement & margin structure
SWOT, moats & dependency map
Supplier–customer ecosystem graph
Signals, trends & valuation range

See plans

Not investment advice — analyst work product for a qualified professional.· intel vintage 2026-07 (FY2025 annual report published 2026-03-05; Q1 2026 reported 2026-05-13; market data late-June 2026; EUR/USD approx 1.14)· sign in (free) for the analyst summary; Pro unlocks full intelligence